We are live on ! Find out more
EC

EntryPoint Capital Portfolio holdings

AUM $412M
1-Year Est. Return 28.52%
This Fund
S&P 500
This Quarter Est. Return
+15.49%
1 Year Est. Return
+28.52%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$412M
AUM Growth
+$70.8M
Cap. Flow
+$36.5M
Cap. Flow %
8.87%
Top 10 Hldgs %
4.34%
Holding
1,002
New
271
Increased
170
Reduced
168
Closed
234

Top Buys

Rank Stock Value
1
HBAN icon
Huntington Bancshares
HBAN
+$1.67M
2
DCI icon
Donaldson
DCI
+$1.6M
3
FDX icon
FedEx
FDX
+$1.6M
4
FNF icon
Fidelity National Financial
FNF
+$1.53M
5
GGG icon
Graco
GGG
+$1.51M

Top Sells

Rank Stock Value
1
CDNS icon
Cadence Design Systems
CDNS
+$1.48M
2
TIC
TIC Solutions Inc
TIC
+$1.48M
3
SDGR icon
Schrodinger
SDGR
+$1.27M
4
EXC icon
Exelon
EXC
+$1.23M
5
VC icon
Visteon
VC
+$1.22M

Sector Composition

Rank Sector Weight
1 Industrials 18.1%
2 Financials 16.8%
3 Healthcare 15.07%
4 Technology 12.86%
5 Consumer Discretionary 9.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SHIP icon
476
Seanergy Maritime Holdings
SHIP
$410M
$353K 0.09%
+26,264
New +$396K
FORM icon
477
FormFactor
FORM
$8.12B
$353K 0.09%
2,205
-2,704
-55% -$359K
MCFT icon
478
MasterCraft Boat Holdings
MCFT
$585M
$352K 0.09%
13,614
-2,796
-17% -$65.1K
KVYO icon
479
Klaviyo
KVYO
$5.3B
$351K 0.09%
+23,249
New +$385K
XYL icon
480
Xylem
XYL
$24.7B
$350K 0.08%
2,958
BH.A icon
481
Biglari Holdings Class A
BH.A
$1.23B
$349K 0.08%
+166
New +$272K
NIC icon
482
Nicolet Bankshares
NIC
$3.61B
$349K 0.08%
2,110
-1,494
-41% -$221K
NEO icon
483
NeoGenomics
NEO
$2.23B
$348K 0.08%
+23,869
New +$230K
GSK icon
484
GSK
GSK
$100B
$348K 0.08%
+6,632
New +$351K
TALO icon
485
Talos Energy
TALO
$2.81B
$347K 0.08%
26,860
+13,907
+107% +$207K
ANIP icon
486
ANI Pharmaceuticals
ANIP
$1.64B
$346K 0.08%
+4,181
New +$335K
UPS icon
487
United Parcel Service
UPS
$87B
$346K 0.08%
+3,215
New +$334K
FLO icon
488
Flowers Foods
FLO
$1.33B
$345K 0.08%
43,702
BANR icon
489
Banner Corp
BANR
$2.61B
$345K 0.08%
5,194
DFTX
490
Definium Therapeutics
DFTX
$5.12B
$345K 0.08%
+7,331
New +$181K
BCS icon
491
Barclays
BCS
$90.6B
$343K 0.08%
12,772
RSI icon
492
Rush Street Interactive
RSI
$3.08B
$341K 0.08%
11,481
-16,700
-59% -$440K
AXSM icon
493
Axsome Therapeutics
AXSM
$10.8B
$340K 0.08%
+1,391
New +$302K
PGNY icon
494
Progyny
PGNY
$1.99B
$340K 0.08%
+11,783
New +$263K
ZETA icon
495
Zeta Global
ZETA
$7.87B
$339K 0.08%
17,221
BLND icon
496
Blend Labs
BLND
$364M
$336K 0.08%
+196,743
New +$314K
HRMY icon
497
Harmony Biosciences
HRMY
$2.46B
$336K 0.08%
9,239
-15,025
-62% -$474K
PARR icon
498
Par Pacific Holdings
PARR
$4.07B
$335K 0.08%
5,971
IDXX icon
499
Idexx Laboratories
IDXX
$42.2B
$334K 0.08%
635
-853
-57% -$478K
TOST icon
500
Toast
TOST
$19.6B
$332K 0.08%
11,932

Similar funds

EntryPoint Capital's Q2 2026 Portfolio in Review

As of Q2 2026, EntryPoint Capital held 1,002 positions worth $412M, up 21% from $341M the previous quarter. Its ten largest holdings account for 4.3% of the portfolio.

EntryPoint Capital deployed $36.5M of net new capital in Q2 2026, opening 271 new positions and adding to 170 existing holdings. Its largest new stake was Huntington Bancshares: 101,010 shares worth $1.79M.

By sector, the portfolio is most concentrated in Industrials at 18% of assets, down from 19% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Cadence Design Systems, an estimated $1.48M trimmed.

  • EntryPoint Capital's largest Q2 2026 buy was Huntington Bancshares: 101,010 shares worth $1.79M.
  • EntryPoint Capital added most to Gilead Sciences in Q2 2026, an estimated $1.51M increase.
  • EntryPoint Capital's biggest Q2 2026 reduction was Cadence Design Systems, cutting an estimated $1.48M.
  • EntryPoint Capital fully exited Exelon in Q2 2026, selling an estimated $1.23M.
  • EntryPoint Capital's ten largest holdings make up 4.3% of its $412M portfolio in Q2 2026.
  • EntryPoint Capital opened 271 new positions and closed 234 in Q2 2026.
  • EntryPoint Capital's portfolio value rose 21% quarter-over-quarter to $412M.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.